CTS-2016 is under clinical development by CytosinLab Therapeutics and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData, Phase I drugs for Myelodysplastic Syndrome have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CTS-2016’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CTS-2016 overview

CTS-2016 is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), intermediate-to-high risk myelodysplastic syndrome (MDS) and solid tumors including non-small cell lung cancer, triple-negative breast cancer. It is administered by oral route as capsule. The drug candidate acts by targeting AXL and FLT3.

CytosinLab Therapeutics overview

CytosinLab Therapeutics (CytosinLab) is focuses on the field of epigenetics and the development of new drugs that used to accelerate the development of multiple epigenetic targeted new drugs on the Sailan Pharmaceutical pipeline to the clinic. CytosinLab is headquartered in Shanghai, China.

For a complete picture of CTS-2016’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.